Amer Joseph

6.8k total citations · 3 hit papers
48 papers, 4.1k citations indexed

About

Amer Joseph is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, Amer Joseph has authored 48 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Endocrinology, Diabetes and Metabolism, 23 papers in Cardiology and Cardiovascular Medicine and 15 papers in Physiology. Recurrent topics in Amer Joseph's work include Hormonal Regulation and Hypertension (33 papers), Blood Pressure and Hypertension Studies (17 papers) and Diet and metabolism studies (13 papers). Amer Joseph is often cited by papers focused on Hormonal Regulation and Hypertension (33 papers), Blood Pressure and Hypertension Studies (17 papers) and Diet and metabolism studies (13 papers). Amer Joseph collaborates with scholars based in Germany, United States and Denmark. Amer Joseph's co-authors include Luís M. Ruilope, Peter Kolkhof, Peter Rossing, Stefan D. Anker, Bertram Pitt, Christina Nowack, Rajiv Agarwal, George L. Bakris, Patrick Schloemer and George L. Bakris and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Amer Joseph

44 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

2020 1.5k citations George L. Bakris, Rajiv Agarwal et al. New England Journal of Medicine profile →
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

2021 578 citations Rajiv Agarwal, Gerasimos Filippatos et al. European Heart Journal profile →
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

2015 493 citations George L. Bakris, Rajiv Agarwal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amer Joseph Germany	24	2.9k	1.5k	1.0k	884	793	48	4.1k
Christina Nowack Germany	18	3.3k 1.1×	1.8k 1.2×	1.2k 1.2×	1.0k 1.1×	776 1.0×	25	4.5k
Kasper Rossing Denmark	31	1.6k 0.5×	1.6k 1.1×	456 0.5×	619 0.7×	1.5k 1.9×	89	4.1k
Clare Arnott Australia	25	1.4k 0.5×	1.3k 0.9×	491 0.5×	785 0.9×	474 0.6×	117	3.4k
Leanne Dyal Canada	15	1.3k 0.5×	1.9k 1.3×	388 0.4×	326 0.4×	517 0.7×	24	3.2k
Itamar Raz United States	9	4.0k 1.4×	1.1k 0.8×	583 0.6×	1.6k 1.8×	500 0.6×	9	4.7k
Agata Ptaszynska United States	27	2.0k 0.7×	2.4k 1.6×	403 0.4×	902 1.0×	252 0.3×	42	4.1k
KyungAh Im United States	24	3.5k 1.2×	1.5k 1.1×	446 0.4×	1.4k 1.5×	373 0.5×	47	4.7k
Marcel H.A. Muskiet Netherlands	28	2.5k 0.9×	456 0.3×	344 0.3×	870 1.0×	748 0.9×	66	3.5k
Roberto Trevisan Italy	38	2.7k 0.9×	1.3k 0.9×	285 0.3×	771 0.9×	1.8k 2.2×	126	5.3k
Alain Bonnardeaux Canada	27	984 0.3×	1.2k 0.8×	417 0.4×	417 0.5×	606 0.8×	40	2.9k

Countries citing papers authored by Amer Joseph

Since Specialization

Citations

This map shows the geographic impact of Amer Joseph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amer Joseph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amer Joseph more than expected).

Fields of papers citing papers by Amer Joseph

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amer Joseph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amer Joseph. The network helps show where Amer Joseph may publish in the future.

Co-authorship network of co-authors of Amer Joseph

This figure shows the co-authorship network connecting the top 25 collaborators of Amer Joseph. A scholar is included among the top collaborators of Amer Joseph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amer Joseph. Amer Joseph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guffon, Nathalie, Line Borgwardt, Anna Tylki‐Szymańska, et al.. (2024). Extended long‐term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha‐mannosidosis. Journal of Inherited Metabolic Disease. 48(1). e12799–e12799. 2 indexed citations

Filippatos, Gerasimos, Stefan D. Anker, Phyllis August, et al.. (2023). Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 9(2). 183–191. 24 indexed citations

Rosas, Sylvia E., Luís M. Ruilope, Stefan D. Anker, et al.. (2023). Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis. Kidney Medicine. 5(10). 100704–100704. 1 indexed citations

Koya, Daisuke, Stefan D. Anker, Luís M. Ruilope, et al.. (2023). Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis. American Journal of Nephrology. 54(9-10). 370–378. 10 indexed citations

Agarwal, Rajiv, Bertram Pitt, Peter Rossing, et al.. (2023). Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiology. 8(8). 732–732. 21 indexed citations

Agarwal, Rajiv, Bertram Pitt, Biff F. Palmer, et al.. (2022). A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clinical Kidney Journal. 16(2). 293–302. 57 indexed citations

Ruilope, Luís M., Rajiv Agarwal, Stefan D. Anker, et al.. (2022). Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 79(12). 2685–2695. 50 indexed citations

Ruilope, Luís M., Bertram Pitt, Stefan D. Anker, et al.. (2022). Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrology Dialysis Transplantation. 38(2). 372–383. 39 indexed citations

Bakris, George L., Luís M. Ruilope, Stefan D. Anker, et al.. (2022). A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney International. 103(1). 196–206. 46 indexed citations

10.

Filippatos, Gerasimos, Bertram Pitt, Rajiv Agarwal, et al.. (2022). Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial. European Journal of Heart Failure. 24(6). 996–1005. 40 indexed citations

11.

Agarwal, Rajiv, Stefan D. Anker, Bertram Pitt, et al.. (2021). Association of Urine Albumin-to-Creatinine Ratio and Its Early Change with Cardiorenal Outcomes in FIDELIO-DKD: A Mediation Analysis. Journal of the American Society of Nephrology. 32(10S). B5–B5.

12.

Agarwal, Rajiv, Gerasimos Filippatos, Bertram Pitt, et al.. (2021). Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal. 43(6). 474–484. 578 indexed citations breakdown →

13.

Goulooze, Sebastiaan C., Meike Brinker, Amer Joseph, et al.. (2021). Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clinical Pharmacokinetics. 61(3). 451–462. 23 indexed citations

14.

Rossing, Peter, Gerasimos Filippatos, Rajiv Agarwal, et al.. (2021). Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney International Reports. 7(1). 36–45. 101 indexed citations

15.

Kolkhof, Peter, Elke Hartmann, Alexius Freyberger, et al.. (2021). Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. American Journal of Nephrology. 52(8). 642–652. 100 indexed citations

16.

Berg, Paul van den, Roland Heinig, Amer Joseph, et al.. (2021). Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. Clinical Pharmacokinetics. 61(3). 439–450. 14 indexed citations

17.

Bakris, George L., Rajiv Agarwal, Stefan D. Anker, et al.. (2020). Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine. 383(23). 2219–2229. 1495 indexed citations breakdown →

18.

Ruilope, Luís M., Rajiv Agarwal, Stefan D. Anker, et al.. (2019). Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. American Journal of Nephrology. 50(5). 345–356. 154 indexed citations

19.

Heinig, Roland, Henk‐Jan Drenth, Amer Joseph, et al.. (2019). Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clinical Pharmacokinetics. 59(3). 359–370. 26 indexed citations

20.

Joseph, Amer, Barry D. Shur, & Rex A. Hess. (2010). Estrogen, Efferent Ductules, and the Epididymis. Biology of Reproduction. 84(2). 207–217. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact